Metabolic function and weight loss after endoscopic sleeve gastroplasty: resistance is futile
Autor: | Andrew C. Storm, Barham K. Abu Dayyeh |
---|---|
Rok vydání: | 2021 |
Předmět: |
Liver Cirrhosis
medicine.medical_specialty Gastroplasty Coronavirus disease 2019 (COVID-19) Gastroenterology Text mining Non-alcoholic Fatty Liver Disease Weight loss Internal medicine Weight Loss Nonalcoholic fatty liver disease medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies ESG endoscopic sleeve gastroplasty Metabolic function business.industry COVID-19 SARS-coronavirus 2—associated disease medicine.disease Fibrosis Obesity Morbid Editorial NAFLD nonalcoholic fatty liver disease Insulin Resistance medicine.symptom business |
Zdroj: | Gastrointestinal Endoscopy |
ISSN: | 0016-5107 |
DOI: | 10.1016/j.gie.2020.11.022 |
Popis: | Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and is closely associated with obesity and insulin resistance (IR). Weight loss is the best treatment for NAFLD. Endoscopic sleeve gastroplasty (ESG) is a promising endoscopic procedure for treatment of obesity. Our aim is to evaluate the change in IR and estimated hepatic steatosis and fibrosis after ESG.One hundred eighteen patients with obesity and NAFLD underwent ESG and were followed for 2 years. Weight loss was evaluated as % total body weight loss. IR was evaluated using the homeostasis model assessment of insulin resistance (HOMA-IR). The previously validated hepatic steatosis index and NAFLD fibrosis score were used to estimate hepatic steatosis and risk of fibrosis.Patients' mean body mass index was 40 ± 7 kg/mOur results suggest a significant and sustained improvement in estimated hepatic steatosis and fibrosis after ESG in patients with NAFLD. Importantly, we showed an early and weight-independent improvement in insulin resistance, which lasted for 2 years after the procedure. |
Databáze: | OpenAIRE |
Externí odkaz: |